Fibrocell Science (FCSC) Given Coverage Optimism Rating of 0.25

News coverage about Fibrocell Science (NASDAQ:FCSC) has been trending positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Fibrocell Science earned a news impact score of 0.25 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8320124634466 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Several brokerages have commented on FCSC. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. HC Wainwright set a $6.00 target price on shares of Fibrocell Science and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $5.21.

Shares of Fibrocell Science (NASDAQ:FCSC) opened at 2.51 on Thursday. The stock has a 50 day moving average of $3.03 and a 200-day moving average of $2.88. Fibrocell Science has a one year low of $1.57 and a one year high of $4.64. The company’s market capitalization is $36.94 million.

Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). On average, equities analysts forecast that Fibrocell Science will post ($2.17) earnings per share for the current fiscal year.

WARNING: “Fibrocell Science (FCSC) Given Coverage Optimism Rating of 0.25” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Insider Buying and Selling by Quarter for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with's FREE daily email newsletter.

Leave a Reply